Immutep (ASX:IMM) reported progress in its study evaluating the effectiveness of IMP761 in treating autoimmune diseases, with the trial now moving to the Part B dose escalation phase, according to a Thursday filing with the Australian bourse.

This follows the completion of Part A of the placebo-controlled, double-blind first-in-human Phase I study, with no safety issues identified during the single-dose administration.

Dosing under Phase B will move from 0.03 mg/kg up to 0.90 mg/kg.

The clinical-stage biotechnology company expects to acquire the study's first safety data before the end of the year.

Immutep's shares inched up 2% in recent trade.

Price (AUD): $0.31, Change: $+0.0050, Percent Change: +1.64%